Bioworld Technology CO., Ltd.

GCKR (R227) Peptide

Cat No.: BS2059P

Background

Glucokinase (also designated hexokinase IV or GCK) plays a key role in the regulation of glucose-induced insulin secretion. GCK is expressed in pancreatic beta cells, where it functions as a glucose sensor, determining the "set point" for insulin secretion. GCK is also expressed in the liver, where it catalyzes the first step in the disposal of glucose. A lack of glucokinase activity leads to reduced insulin secretion and hyperglycemia and has been implicated as a cause for maturity onset diabetes of the youth (MODY). Heterozygous point mutations in the gene encoding GCK have been detected in individuals suffering from MODY. GCK is regulated by GCKR (glucokinase regulatory protein). GCKR is a 68 kDa protein which is expressed in pancreatic beta cells and in the liver.

Swiss-Prot

Q14397

Applications

Blocking

Specificity

This peptide can be used with studies using BS2059 GCKR (R227) pAb.

Purification & Purity

Synthetic peptide GCKR (R227). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4℃ short term. Aliquot and store at -20℃ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park,MN 55416,USA. **Email: info@bioworlde.com**
Tel: 6123263284 **Fax: 6122933841**

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046, P, R.China. **Email: info@biogot.com**
Tel: +86-025-68037686 **Fax:+86-025-68035151**